Nemaura Medical

Nemaura Medical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Nemaura Medical (NMRD) as of Oct 22, 2026 is 63.57 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 53.72 % — a change of 18.33% (higher).

FCF Conversion

63.57 %

YoY

18.33%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Nemaura Medical is 2023 63.57 % . FCF Conversion Rate (FCF/EBITDA) of Nemaura Medical was 2022 53.72 % . It decreases by 18.33% higher compared to the previous year.

The Nemaura Medical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
84.24 USD
Jan 1, 2017
82.02 USD
Jan 1, 2018
119.87 USD
Jan 1, 2019
81.77 USD
Jan 1, 2020
87.99 USD
Jan 1, 2021
109.20 USD
Jan 1, 2022
53.72 USD
Jan 1, 2023
63.57 USD
The Nemaura Medical FCF Conversion history
YEARFCF ConversionYoY
63.57 %+18.33%
53.72 %-50.80%
109.20 %+24.11%
87.99 %+7.61%
81.77 %-31.79%
119.87 %+46.14%
82.02 %-2.63%
84.24 %-27.10%
115.55 %-145.39%
-254.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nemaura Medical Stock analysis

What does Nemaura Medical do? Nemaura Medical Inc is a medical technology company based in the UK that specializes in the development and marketing of non-invasive medical devices. The company was founded in 2011 and has since brought numerous innovative devices to the market. Nemaura Medical's business model is based on the design, development, and marketing of technology platforms. These platforms are then used for various applications in medical diagnostics and treatment. The different divisions of Nemaura Medical are diabetes, hypoglycemia, blood pressure, and sleep apnea. Each of these divisions focuses on the development and marketing of specific devices needed for their respective application. Nemaura Medical's most well-known product is the SugarBEAT® system, designed for diabetes patients. It is a non-invasive system that continuously monitors blood glucose levels without the need for blood extraction. Instead, a small sensor is attached to the skin, providing measurement data over a certain period of time. Another important division of Nemaura Medical is hypoglycemia. The company has developed a device called SugarBEAT®+ that measures blood glucose levels in real-time and provides an alarm signal to the patient when blood glucose levels are too low. This is important for diabetes patients as hypoglycemia can be a life-threatening condition requiring quick response. Nemaura Medical has also developed a device called BEAT™ for monitoring blood pressure. It is also a non-invasive system where a cuff is placed around the arm. The pressure is continuously monitored, and the data is wirelessly transmitted to a smartphone or computer. Lastly, Nemaura Medical has developed a device used for sleep apnea. It is a small device called SugarBEAT®-Flow that continuously measures the airflow in the respiratory tract. This can determine if the patient is suffering from sleep apnea and if treatment is necessary. The company also works closely with partners in healthcare and medicine to bring its products to market. It has established a number of collaboration agreements to establish its technologies in various application areas. Overall, Nemaura Medical is an innovative company specialized in the development and marketing of non-invasive medical devices. It has developed a wide range of products for various applications in medical diagnostics and treatment and collaborates with partners in healthcare to bring its technologies to market. With its innovative products and dedicated team, Nemaura Medical is on a successful path to improving the lives of patients worldwide. Nemaura Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nemaura Medical stock

FCF Conversion Rate (FCF/EBITDA) of Nemaura Medical is 63.57 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Nemaura Medical changed from 53.72 % to 63.57 %, representing a 18.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Nemaura Medical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Nemaura Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nemaura Medical

All Key Metrics — Nemaura Medical